MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects

Journal of Molecular Neuroscience

Volumn 54, Issue 4, 2014, Pages 830-836

  Cardo, Lucía F ^a   Coto, Eliecer ^a   Ribacoba, René ^b   Menéndez, Manuel ^b   Moris, Germán ^b   Suárez, Esther ^b   Alvarez, Victoria ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Neurología Hospital Universitario Central Asturias and Álvarez Buylla Mieres   (Spain)

Author keywords

MicroRNAs; Parkinson s disease; RNA expression; Substantia nigra

Indexed keywords

MICRORNA;

ALZHEIMER DISEASE; ARTICLE; BIOINFORMATICS; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; HUMAN TISSUE; LUNG CANCER; MACROGLOBULINEMIA; NERVE DEGENERATION; OVARY CANCER; PARKINSON DISEASE; PROSTATE CANCER; RNA EXTRACTION; SCHIZOPHRENIA; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; UTERUS MYOMA; ADULT; AGED; CASE CONTROL STUDY; CHILD; FEMALE; GENE REGULATORY NETWORK; GENETICS; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE REGULATORY NETWORKS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84914097024     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0428-y     Document Type: Article

References (37)

1. Alvarez-Erviti L, Seow Y, Schapira AH, Rodriguez-Oroz MC, Obeso JA, Cooper JM (2013) Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson’s disease. Cell Death Dis 4:e545
2. Bekris LM, Lutz F, Montine TJ et al (2013) MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 18:455–466
3. Botta-Orfila T, Morato X, Compta Y et al (2014) Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson’s disease. J Neurosci Res 92:1071–1077
4. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134
5. Cardo LF, Coto E, de Mena L et al (2013) Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls. J Neurol 260:1420–1422
6. Cardo LF, Coto E, de Mena L et al (2014a) Alpha-synuclein transcript isoforms in three different brain regions from Parkinson’s disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci Lett 562:45–49
7. Cardo LF, Coto E, Ribacoba R et al (2014b) The screening of the 3′UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson’s disease. J Hum Genet 59:346–348
8. Chatterjee P, Bhattacharyya M, Bandyopadhyay S, Roy D (2014) Studying the system-level involvement of microRNAs in Parkinson’s disease. PLoS One 9:e93751
9. Cho HJ, Liu G, Jin SM et al (2012) MicroRNA-205 regulates the expression of Parkinson’s disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 22:608–620
10. De Mena L, Cardo LF, Coto E, Alvarez V (2013) No differential DNA methylation of PARK2 in brain of Parkinson’s disease patients and healthy controls. Mov Disord 28:2032–2033
11. Doxakis E (2010) Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 285:12726–12734
12. Eacker SM, Dawson TM, Dawson VL (2009) Understanding microRNAs in neurodegeneration. Nat Rev Neurosci 10:837–841
13. Faghihi MA, Zhang M, Huang J et al (2010) Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol 11:R56
14. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637–641
15. Gilad S, Meiri E, Yogev Y et al (2008) Serum microRNAs are promising novel biomarkers. PLoS One 3:e3148
16. Hansen T, Olsen L, Lindow M et al (2007) Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2:e873
17. Jung M, Schaefer A, Steiner I et al (2010) Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 56:998–1006
18. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM (2009) Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A 106:13052–13057
19. Khoo SK, Petillo D, Kang UJ et al (2012) Plasma-based circulating microRNA biomarkers for Parkinson’s disease. J Park Dis 2:321–331
20. Kim J, Inoue K, Ishii J et al (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317:1220–1224
21. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294:853–858
22. Lai CY, Yu SL, Hsieh MH et al (2011) MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 6:e21635
23. Liao XY, Wang WW, Yang ZH et al (2013) Microarray analysis of transcriptome of medulla identifies potential biomarkers for Parkinson’s disease. Int J Genom 2013:606919
24. Long JM, Ray B, Lahiri DK (2014) MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289:5184–5198
25. Maciotta S, Meregalli M, Torrente Y (2013) The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7:e265
26. Martins M, Rosa A, Guedes LC et al (2011) Convergence of miRNA expression profiling, alpha-synuclein interaction and GWAS in Parkinson’s disease. PLoS One 6:e25443
27. Minones-Moyano E, Porta S, Escaramis G et al (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20:3067–3078
28. Minones-Moyano E, Friedlander MR, Pallares J et al (2013) Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction. RNA Biol 10:1093–1106
29. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31:763–780
30. Olsen L, Klausen M, Helboe L, Nielsen FC, Werge T (2009) MicroRNAs show mutually exclusive expression patterns in the brain of adult male rats. PLoS One 4:e7225
31. Palacín M, Reguero JR, Martín M et al (2011) Profile of microRNAs differentially produced in hearts from patients with hypertrophic cardiomyopathy and sarcomeric mutations. Clin Chem 57:1614–1616
32. Prior C, Perez-Gracia JL, Garcia-Donas J et al (2014) Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 9:e86263
33. Sonntag KC (2010) MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res 1338:48–57
34. Soreq L, Salomonis N, Bronstein M et al (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci 6:e10
35. Vallelunga A, Ragusa M, Di Mauro S et al (2014) Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and multiple system atrophy. Front Cell Neurosci 8:156
36. Wang G, van der Walt JM, Mayhew G et al (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82:283–289
37. Zahm AM, Thayu M, Hand NJ, Horner A, Leonard MB, Friedman JR (2011) Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 53:26–33